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Chemotherapy and radiation therapy may increase risk for interstitial pneumonitis (IP) in breast cancer patients, but there are little
current population-based data on IP incidence in these patients. We assessed population-based incidence rates (IRs) of IP among
Danish breast cancer patients and compared these with IRs for the Danish general population. Through the Danish Cancer Registry,
we identified all Danish breast cancer patients (n¼35823) diagnosed between 1994 and 2004. Treatment data were obtained from
the Danish Breast Cancer Cooperation Group database, and data on IP, from the Danish National Registry of Patients. We computed
IRs of IP among breast cancer patients and age-standardised incidence rate ratios (SIRs) comparing breast cancer patients with the
general population. During follow-up, 28 breast cancer patients were registered with an IP diagnosis (IR¼17.3 per 100000 person-
years (p-y) (95% confidence intervals (95% CI): 11.7–24.6)). When follow-up was restricted to 1 year after the first breast cancer
diagnosis, eight patients with IP were identified (IR¼23.4 per 100000 p-y (95% CI: 11.0–44.1)). The SIR comparing breast
cancer patients with the general population was 8.4 (95% CI: 5.7–11.9). Thus, although IP is a rare adverse event among breast
cancer patients, its risk is substantially higher than that in the general population.
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The improved prognosis and cure rates of breast cancer in recent
decades underscore the need for data on chronic diseases and
treatment sequelae (Cronin-Fenton et al, 2007). Interstitial lung
diseases (ILDs) are a large and heterogeneous group of pulmonary
fibrotic disorders, including interstitial pneumonitis (IP). Most
cases of IP are of unknown cause (Camus et al, 2004; Raghu et al,
2004). Pulmonary drug toxicity is a common and possibly
underdiagnosed cause of ILDs (Camus et al, 2004). It has been
suggested that well-established breast cancer treatments, including
tamoxifen and taxanes, increase the risk of IP, particularly when
combined with adjuvant radiation therapy (Taghian et al, 2001; Yu
et al, 2004; Burstein et al, 2006; Dimopoulou et al, 2006). Most of
these studies of IP incidence among breast cancer patients are
clinic-based case series without control groups, or reports based
on data from clinical trials. Such trials often include small, highly
selected study populations, limiting generalisability of their
findings (Taghian et al, 2001; Yu et al, 2004; Burstein et al, 2006;
Sorensen et al, 2006). Thus, it remains unclear whether, and to
what extent, breast cancer is associated with later IP in a
population-based setting. Owing to the low incidence of IP, studies
of this condition generally require very large cohorts of breast
cancer patients. Denmark’s nationwide population-based health
registries enable investigation of the incidence of this rare disease
(Frank, 2000). In this population-based cohort study, we examined
the incidence of IP among breast cancer patients and compared it
with IP incidence in the Danish general population.
MATERIALS AND METHODS
Setting and design
We conducted this nationwide cohort study from 1 January 1994 to
31 December 2004, using data from Danish population-based
health registries. The study’s start date was chosen because on
1 January 1994 the Danish National Registry of Patients (NRP)
replaced the eighth revision of the International Classification of
Diseases (ICD) with the 10th revision for coding of the diagnoses.
The 10th revision provides for more detailed coding of ILDs
(Andersen et al, 1999).
The tax-funded National Health Service guarantees for all
Danish residents access to health care, including free access to
general practitioners, other primary medical care clinics, and all
hospitals. In Denmark, public hospitals provide breast cancer
patient care, including management of complications, such as IP,
that arise during treatment.
Since 1968, the Danish Civil Registration System (CRS) has
maintained electronic records for all Danish residents, including
gender, date of birth, changes of address, dates of emigration, and
changes in vital status (Frank, 2000). The 10-digit unique civil
registration number assigned to every Danish resident is a unique
personal identifier, enabling unambiguous linkage of records for this
study from the NRP, the Danish Cancer Registry (DCR), the Danish
Breast Cancer Cooperation Group (DBCG) database, and the CRS.
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We identified all first-time breast cancer patients (n¼35823)
registered from 1994 to 2004 in the DCR (Jensen et al, 2002).
The DCR is a population-based nationwide registry of all
incident cases of cancer diagnosed in Denmark since 1943. The
registry receives notifications of new diagnoses from hospital
departments (including departments of pathology and forensic
medicine), general practitioners, and practising specialists; the
reported diagnoses are reclassified according to the modified
seventh revision of International Classification of Diseases (ICD-
7). For each case, the DCR also includes the patient’s civil
registration number, method of cancer verification, and tumour
clinical stage according to the Summary Stage Classification. We
used the following ICD-7 codes to identify breast cancer patients:
470.0–470.5, 870.0, 870.1, and 870.2. We excluded two patients
who were registered with an IP diagnosis in the NRP before the
date of their first breast cancer diagnosis. We grouped patients
into four groups according to tumour stage at diagnosis (localised
cancer only, regional metastases, distant metastases, and un-
known).
The DBCG was established in 1976 with the purpose of collecting
high-quality clinical, patient and treatment information on all
breast cancer cases to ensure optimal diagnosis and treatment and
to recruit patients to trials (Andersen and Mouridsen, 1988;
Overgaard et al, 1997). Through the DBCG database, we obtained
data on radiation therapy (breast alone or breast and axillary/
neck), tamoxifen treatment, and chemotherapy for 22748 (63.5%)
breast cancer patients registered in DBCG between 1994 and 2004
and treated according to a prespecified protocol.
Interstitial pneumonitis
The NRP contains data on all non-psychiatric hospital admissions
in Denmark since 1977 and on all outpatient contacts, including
ambulatory and emergency department visits, since 1995. Data
include patients’ civil registration numbers, dates of hospital
admission and discharge, and up to 20 diagnoses (Andersen et al,
1999). We used the NRP to identify all hospital contacts during the
1994–2005 period for breast cancer patients registered with a
primary or secondary diagnosis of IP associated with external
agents (ICD-10 codes: J70.0-J70.9). We also used the NRP to obtain
data on all diagnoses of IP in the general population registered
between 1994 and 2005 inclusive.
Validation of discharge diagnoses of IP
As hospital discharge diagnoses are not completely accurate
(Sørensen, 1997), we evaluated the quality of the J.70.X diagnosis
in the NRP by reviewing the hospital records of all patients
registered with an IP diagnosis between 1994 and 2005 in North
Jutland County (n¼53). We confined the review to North Jutland
County, which encompasses 10% of the entire Danish population,
because of the uniform data quality in the county hospital
discharge registries supplying data to the NRP.
Surgical lung biopsy is considered the gold standard for IP
diagnosis (Hunninghake et al, 2001; Swigris et al, 2005), although
the reproducibility of biopsy-proven ILDs has been shown to be
low. In a clinical setting, lung biopsies are rarely performed
because of potential complications, particularly prolonged pneumo-
thorax in frail high-risk patients (Swigris et al, 2005). In the
absence of biopsy data, we considered a discharge diagnosis of IP
to be confirmed if the hospital record clearly stated that the patient
had IP and if the diagnosis was not changed during further
diagnostic work-up. We computed the positive predictive value
(PVþ) of an IP discharge diagnosis as the percentage of cases in
the hospital record sample under review that fulfilled these criteria
(Sorensen et al, 1996).
Statistical analyses
We computed incidence rates (IR) of IP as the number of
new IP cases per 100000 person-years (p-y) of follow-up.
Time at risk for breast cancer patients was computed as
time from the first breast cancer diagnosis to the first IP
diagnosis, death, emigration (obtained through linkage to the
Danish CRS) or 31 December 2004, whichever came first. Then, we
restricted follow-up time for IP to 1 year after the first breast
cancer diagnosis. Time at risk for the general population was
defined by the number of citizens alive in Denmark in the middle
of the study period, that is, 1999 (obtained from Statistics
Denmark). We repeated the analysis of IR for radiation-induced
pneumonitis including patients treated with radiation therapy
only.
We compared the number of observed IP cases among breast
cancer patients with the number of expected IP cases in Denmark’s
general population by computing, as a measure of relative risk,
standardised incidence ratios (SIR) as the ratio of the observed to
the expected number of IP cases. Interstitial pneumonitis IRs per
100000 p-y of follow-up by sex and age were computed for the
general population. They were then applied to the p-y of
observation for breast cancer patients to obtain the number of
IP cases expected, if breast cancer patients had experienced the
same IP rates as the general population. Ninety-five percent
confidence intervals (95% CI) were computed for each SIR,
assuming a Poisson distribution for the observed number of IP
cases.
All statistical analyses were performed using SAS software
(version 9.1.3, SAS Institute Inc., Cary, NC, USA).
RESULTS
Incidence of IP
We identified 35823 first-time breast cancer patients with a total
follow-up time of 162354 years (Table 1). The majority of breast
cancer patients was between 50 and 70 years of age and most had
regional metastases at time of diagnosis. Twenty-eight breast
cancer patients were subsequently registered with a diagnosis of
IP, corresponding to an IR of 17.3 (95% CI: 11.7–24.6) per 100000
p-y (Figure 1). Twenty-four (85.7%) of the IP patients were only
registered with one hospitalisation or outpatient contact for IP.
Most IPs occurred among patients between 50 and 70 years of age
(n¼19, IR¼22.6 (95% CI: 14.0–34.5) per 100000 p-y). The
majority of IP cases occurred in patients with regional metastases
(n¼18, IR¼30.4 (95% CI: 18.6–46.9) per 100000 p-y). The
highest IR was among breast cancer patients with distant
metastases (IR¼60.7 (95% CI: 12.1–194.6) per 100000 p-y), but
this estimate, based on six cases, is statistically imprecise. With
the exception of two IP cases recorded as drug-induced, the IPs
were recorded as radiation-induced (92.6%). Eight cases of IP
occurred within 1 year after the first breast cancer diagnosis,
corresponding to an IR of 23.4 (95% CI: 11.0–44.0) per 100000 p-y
(Table 2). All these cases were documented as being radiation-
induced.
Restricting the analysis to patients registered with complete
treatment data in the DBCG database (n¼22748) (63.5%) and
treated with radiation therapy (n¼8090) left 14 cases of radiation-
induced IP (IR¼31.5 (95% CI: 18.5–51.5) per 100000 p-y)
(Table 3). With one exception, all cases were among patients
treated with extensive radiation therapy (IR¼56.9 (95% CI: 31.9–
94.6) per 100000 p-y); the remaining IP case was registered among
patients treated with localised radiation therapy (IR¼4.6 (95% CI:
0.4–21.6) per 100000 p-y). The highest IR was found among
patients treated with a combination of radiation and tamoxifen
(IR¼103.9 (95% CI: 46.3–204.5) per 100000 p-y) or with a
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16.1–93.2) per 100000 p-y). For patients treated with radiation,
only the IR was 8.8 (95% CI: 1.7–28.1) per 100000 p-y.
The overall SIR comparing IRs of IP among breast
cancer patients with those in the general population was
8.4 (95% CI: 5.7–11.9), ranging from 28.9 (95% CI: 19.3–41.7)
for radiation-induced IP to 1.5 (95% CI: 0.3–4.8) for drug-induced
IP (Table 4).
Validity of IP diagnoses
In the reviewed sample of 53 episodes of patients registered
with IP, 41 episodes fulfilled criteria for confirmed IP, equivalent
to a PV of 77% (95% CI: 63–89%). A total of 22 of 24 episodes
registered as drug-induced IP fulfilled the criteria for IP (PV 92%
(95% CI: 73–98%)) and 22 of 24 IPs registered as
radiation-induced fulfilled our criteria (PV 87% (95% CI:
59–98%)). In all patients with a confirmed cancer diagnosis
(14 of 53 patients), the IP diagnosis was considered correct. Most
patients were diagnosed based on clinical and chest X-ray findings.
Only four patients (7%) had lung-biopsy-confirmed
diagnosis. High-resolution CT scans confirmed the diagnosis in
eight patients (14%). The 12 patients with IP not confirmed by
validation actual diagnoses included chronic obstructive pulmo-
nary disease, asthma, congestive heart failure, or idiopathic
pulmonary fibrosis.
DISCUSSION
In a well-defined North European population, drug- or radiation
therapy-induced IP requiring hospitalisation was a rare adverse
event among breast cancer patients. However, the excess risk was
substantial compared with that of the general population. Most
cases of IP were considered radiation-induced and occurred more
than 1 year following the initial breast cancer diagnosis. The
highest IR was found among patients treated with radiation
therapy and tamoxifen.
The strengths of our study include the uniformly organised
Danish public health-care system, enabling a truly population-
based design with little opportunity for diagnostic or referral bias.
Further, we were able to include all patients with first-time
hospitalisation for breast cancer; had access to detailed informa-
tion on their cancer treatment; and had complete long-term follow-
up for patients hospitalised with IP. The validity and completeness
of breast cancer diagnosis recorded in the DCR has been shown to
be very high (Jensen et al, 2002). The validity of our estimates thus
depends ultimately on the quality of IP data in the Danish NRP,
which is a function of diagnostic and coding practises. We found
an acceptable positive predictive value of drug- and radiation-
induced IP requiring hospitalisation, which was in the same range
as for most other diseases reported in this registry (Sørensen,
1997).
Our study has several important limitations. Interstitial lung
diseases are difficult to diagnose clinically (Raghu et al, 2004) and
Table 1 Incidence of interstitial pneumonitis (IP) among 35823 Danish breast cancer patients by age and cancer stage, Denmark 1994–2004
Number of breast
cancer patients (%)
Number of IP
patients (%)
Incidence rate per
100000 person-years (95% CI)
IP unspecified
Overall 35823 (100%) 28 (100%) 17.3 (11.7–24.6)
Age groups (years)
o50 7119 (19.9%) 6 (21.4%) 16.4 (6.8–33.7)
50–70 17694 (49.4%) 19 (67.9%) 22.6 (14.0–34.5)
470 11010 (30.7%) 3 (10.7%) 7.3 (2.1–19.3)
Cancer stage
a
Localised cancer, no metastasis 13746 (38.4%) 2 (7.1%) 6.9 (2.9–14.3)
Regional metastases 16841 (47.0%) 18 (64.3%) 30.4 (12.6–46.9)
Distant metastases 1881 (5.2%) 6 (21.4%) 60.7 (12.1–194.6)
Unknown 3355 (9.4%) 2 (7.1%) 14.8 (2.9–47.6)
IP radiation-induced
Overall 35823 (100%) 26 (100%) 16.0 (10.7–23.1)
Age groups (years)
o50 7119 (19.9%) 6 (23.1%) 16.4 (6.8–33.7)
50–70 17694 (49.4%) 17 (65.4%) 20.7 (12.2–31.6)
470 11010 (30.7%) 3 (11.5%) 7.3 (2.0–19.3)
Cancer stage
a
Localised cancer, no metastasis 13746 (38.4%) 2 (7.7%) 4.6 (1.6–11.0)
Regional metastases 16841 (47.0%) 18 (69.2%) 60.7 (12.1–194.6)
Distant metastases 1881 (5.2%) 2 (7.7%) 30.4 (18.6–46.9)
Unknown 3355 (9.4%) 2 (7.7%) 14.8 (2.9–47.6)
IP drug-induced
Overall 35823 (100%) 2 (100%) 1.2 (0.25–3.9)
Age groups (years)
o50 7119 (19.9%) 0 —
50–70 17694 (49.4%) 2 (100%) 2.4 (0.5–7.6)
470 11010 (30.7%) 0 —
Cancer stage
a
Localised cancer, no metastasis 13746 (38.4%) 0 —
Regional metastases 16841 (47.0%) 0 —
Distant metastases 1881 (5.2%) 2 (100%) 2.3 (0.5–7.4)
Unknown 3355 (9.4%) 0 —
aCancer stage according to summary stage classification.
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patients undergoing surgical lung biopsy or high-resolution CT
scans (Hunninghake et al, 2001; Cleverley et al, 2002). Our data
lacked clinical detail and, as in other ILD registry-based studies, we
were unable to apply the new classification of Diffuse Parenchymal
Lung Disease (DPLD) to the ICD-10 diagnosis in the Danish NRP
(Raghu et al, 2004). As this study aimed to examine adverse effects
of breast cancer treatment, our focus was on DPLD cases caused by
external agents such as drugs, including chemotherapy, and
radiation therapy. The high SIR for IP among breast cancer
patients should be interpreted with caution because radiation-
induced IP was defined in terms of the exposure, that is radiation
therapy (Rothman, 2002), and because the majority of persons in
the general population were not treated with radiation therapy and
they were therefore not at risk for radiation-induced IP. Still, the
SIR allowed us to quantify the excess IP risk among breast cancer
patients.
In addition, by using hospital diagnoses to identify IP
cases, we may have missed patients with few or mild
symptoms of IP. Consequently, the IP IRs observed in our study
must be viewed as conservative estimates of the true IRs. Still,
inclusion of outpatient data in the NRP from 1995 onwards
increased the sensitivity of the data by reducing underreporting of
mild IP. We lacked data on severity of IP symptoms, and the
number of hospitalisations may be a poor proxy measure of
severity because patients with severe IP may die soon after first IP
hospitalisation.
Compared with the general population, breast cancer patients
are in closer and more regular contact with the health-care system,
so that greater observed risk of IP among them may be partly
explained by surveillance bias. On the other hand, it is also
possible that diagnostic neglect of end-stage breast cancer patients
in the health-care system led to underestimation of IP incidence in
this group.
Despite the limitations discussed above, the IP IRs we
identified in the general population were in the same range as
those reported by the only two other population-based studies on
this condition, conducted in New Mexico, USA, and Southern
Spain (Coultas et al, 1994; Lopez-Campos and Rodriguez-Becerra,
2004). This provides confirmation for the methodological strength
of our study.
Despite the availability of complete nationwide follow-up
for IP among all breast cancer patients during the 10-year
study period, the number of observed IP cases was small,
and it is difficult to interpret the resulting imprecise estimates.
As chemotherapy and radiation therapy, and particularly the
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Figure 1 Cumulative incidence in percent of IP among 35823 Danish
breast cancer patients (1994–2004).
Table 2 Incidence of interstitial pneumonitis (IP) cases registered within one year following initial breast cancer diagnosis, by age and cancer stage,
Denmark 1994–2004
Number of breast
cancer patients (%)
Number of IP
patients (%)
Incidence rate per 100000
person-years (95% CI)
IP unspecified
Overall 35823 (100%) 8 (100%) 23.4 (11.0–44.0)
Age groups (years)
o50 7119 (19.9%) 2 (25.0%) 28.4 (5.7–91.1)
50–70 17694 (49.4%) 6 (75.0%) 34.9 (14.5–71.8)
470 11010 (30.7%) 0 —
Cancer stage
a
Localised cancer, no metastasis 13746 (38.4%) 0 —
Regional metastases 16841 (47.0%) 7 (87.5%) 52.2 (23.3–102.5)
Distant metastases 1881 (5.2%) 0 —
Unknown 3355 (9.4%) 1 (12.5%) 33.1 (3.0–154.5)
IP radiation-induced
Overall 35823 (100%) 8 (100%) 23.4 (11.0–44.1)
Age groups (years)
o50 7119 (19.9%) 2 (25.0%) 28.4 (5.7–91.1)
50–70 17694 (49.4%) 6 (75.0%) 34.9 (14.5–71.9)
470 11010 (30.7%) 0 —
Cancer stage
a
Localised cancer, no metastasis 13746 (38.4%) 0 —
Regional metastases 16841 (47.0%) 7 (87.5%) 52.2 (23.3–102.5)
Distant metastases 1881 (5.2%) 0 —
Unknown 3355 (9.4%) 1 (12.5%) 33.1 (3.0–154.5)
IP drug-induced
Overall 35823 (100%) 0 —
aCancer stage according to summary stage classification.
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incidence of IP among breast cancer patients to be higher
than in the general population (Taghian et al, 2001;
Burstein et al, 2006). However, there are no population-based
data on the magnitude of this increased risk. In two
recent US randomised controlled trials examining the risk of
pneumonitis among breast cancer patients treated with taxanes,
the proportion of patients developing pneumonitis was as high as
15% (Taghian et al, 2001; Burstein et al, 2006). However,
generalisation of these results to all patients with breast cancer is
complicated by the fact that these populations are highly selected
and closely monitored (Sorensen et al, 2006). Our findings of the
highest IR of IP among patients treated with radiation therapy and
tamoxifen is in line with previous findings, suggesting that
tamoxifen mediates the enhancement of radiation-induced lung
fibrosis, possibly by inducing transforming growth factor-b
secretion (Bentzen et al, 1996).
Cancer treatment is the suggested mechanism underlying the
association between cancer and IP. Since lung tissue is included in
radiotherapy of breast cancer, these patients have a higher risk of
radiation-induced IP than patients with other solid tumours. This
is corroborated by our findings of a much higher IR of IP among
patients with documented radiation therapy and by greater IRs
seen among breast cancer patients treated with extensive vs
localised radiation. It is, therefore, questionable whether the IRs of
IP in our study can be validly generalised to other cancer patients.
In conclusion, IP is a rare adverse event among breast cancer
patients, but the risk is substantially higher than that in the general
population.
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